Inclusion Criteria:
* Aged 30-70, meeting the diagnostic criteria for Refractory Familial Cortical Myoclonus with Epilepsy (FCMTE), meaning that tremors and/or seizures have not significantly improved despite long-term, stable use of current treatment medications, regardless of gender.
* Tremors and seizures severely impact the patients\' work and quality of life.
* Experiencing drug resistance or intolerable adverse reactions to medication.
* After being adequately informed about the nature and risks of the study, willing to provide written informed consent before participating in any study-related procedures.
* Willing to adhere to the relevant trial protocol and regulations, including attending follow-up visits and undergoing related examinations within the specified timeframe.
Exclusion Criteria:
* Patients with FCMTE whose symptoms are essentially controlled after standardized medication and other treatments.
* Presence of structural abnormalities in the VIM (ventral intermediate nucleus).
* Presence of an implanted electrical stimulator (e.g., pacemaker, spinal cord stimulator, repetitive nerve stimulator) or metallic implants in the head (e.g., aneurysm clips, cochlear implants). Note: Vagus nerve stimulation (with stable parameters for at least 3 months) is not an exclusion criterion.
* IQ \< 55, severe cognitive impairment that prevents participation in the study.
* Pregnant individuals or those planning to conceive within 2 years.
* Presence of progressive neurological diseases such as brain tumors, arteriovenous malformations, or cavernous hemangiomas.
* Presence of other serious neuropsychiatric disorders such as dementia, severe depression (hospitalized in a psychiatric facility within the past 5 years or any suicidal or self-harming tendencies), schizophrenia, or neurodegenerative diseases. Resolved postictal psychiatric or behavioral abnormalities are not an exclusion criterion.
* Conditions that may increase the risk of seizures during or after surgery (e.g., coagulation disorders) or require long-term oral anticoagulants or antiplatelet drugs.
* Other severe physical illnesses, psychiatric disorders, internal diseases, or severe liver or kidney dysfunction; participation in other clinical trials within the past three months.
